Catherine R Armbruster
Overview
Explore the profile of Catherine R Armbruster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hilliam Y, Armbruster C, Rapsinski G, Marshall C, Moore J, Koirala J, et al.
Microbiol Spectr
. 2024 Jun;
12(8):e0078724.
PMID: 38916354
Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has revolutionized the treatment of cystic fibrosis (CF) for most affected individuals but the effects of treatment on sinus microbiota are still unknown. Changes to the airway...
2.
Rapsinski G, Michaels L, Hill M, Yarrington K, Haas A, DAmico E, et al.
PLoS Pathog
. 2024 May;
20(5):e1011453.
PMID: 38820569
Mucosa-associated biofilms are associated with many human disease states, but the host mechanisms promoting biofilm remain unclear. In chronic respiratory diseases like cystic fibrosis (CF), Pseudomonas aeruginosa establishes chronic infection...
3.
Zamora P, Reidy T, Armbruster C, Sun M, Van Tyne D, Turner P, et al.
PLoS Biol
. 2024 Apr;
22(4):e3002566.
PMID: 38652717
Phage therapy is a therapeutic approach to treat multidrug-resistant (MDR) infections that employs lytic bacteriophages (phages) to eliminate bacteria. Despite the abundant evidence for its success as an antimicrobial in...
4.
Armbruster C, Hilliam Y, Zemke A, Atteih S, Marshall C, Moore J, et al.
mBio
. 2024 Apr;
15(5):e0051924.
PMID: 38564694
Importance: The highly effective cystic fibrosis transmembrane conductance regulator modulator therapy Elexakaftor/Tezacaftor/Ivacaftor (ETI) has changed cystic fibrosis (CF) disease for many people with cystic fibrosis. While respiratory symptoms are improved...
5.
Zamora P, Reidy T, Armbruster C, Sun M, Van Tyne D, Turner P, et al.
bioRxiv
. 2024 Feb;
PMID: 38370761
Phage therapy is a therapeutic approach to treat multidrug resistant infections that employs lytic bacteriophages (phages) to eliminate bacteria. Despite the abundant evidence for its success as an antimicrobial in...
6.
Atteih S, Armbruster C, Hilliam Y, Rapsinski G, Bhusal J, Krainz L, et al.
Pediatr Pulmonol
. 2024 Feb;
59(5):1266-1273.
PMID: 38353361
Background: While the widespread initiation of elexacaftor/tezacaftor/ivacaftor (ETI) has led to dramatic clinical improvements among persons with cystic fibrosis (pwCF), little is known about how ETI affects the respiratory mucosal...
7.
Haas A, Zemke A, Melvin J, Armbruster C, Hendricks M, Moore J, et al.
Cell Rep
. 2023 Mar;
42(3):112270.
PMID: 36930643
The cystic fibrosis (CF) respiratory tract harbors pathogenic bacteria that cause life-threatening chronic infections. Of these, Pseudomonas aeruginosa becomes increasingly dominant with age and is associated with worsening lung function...
8.
Armbruster C, Li K, Kiedrowski M, Zemke A, Melvin J, Moore J, et al.
Microbiol Spectr
. 2022 Sep;
10(5):e0125122.
PMID: 36094193
Chronic rhinosinusitis (CRS) is a common, yet underreported and understudied manifestation of upper respiratory disease in people with cystic fibrosis (CF). Recently developed standard of care guidelines for the management...
9.
Garber A, Armbruster C, Lee S, Cooper V, Bomberger J, McAllister S
BMC Genomics
. 2022 Mar;
23(1):202.
PMID: 35279076
Background: Shotgun sequencing of cultured microbial isolates/individual eukaryotes (whole-genome sequencing) and microbial communities (metagenomics) has become commonplace in biology. Very often, sequenced samples encompass organisms spanning multiple domains of life,...
10.
Armbruster C, Marshall C, Garber A, Melvin J, Zemke A, Moore J, et al.
Cell Rep
. 2021 Oct;
37(3):109829.
PMID: 34686349
Pseudomonas aeruginosa notoriously adapts to the airways of people with cystic fibrosis (CF), yet how infection-site biogeography and associated evolutionary processes vary as lifelong infections progress remains unclear. Here we...